In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on shares of Regeneron Pharmaceuticals (REGN) and a $382 price target, after REGN and partner …
In a research note released Monday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals, Inc. (REGN) and a price target of $382.
